Related references
Note: Only part of the references are listed.Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Correction: PARP-1 inhibitor modulate β-catenin signaling to enhance cisplatin sensitivity in cancer cervix
Minakshi Mann et al.
Oncotarget (2019)
EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer
H. Yamaguchi et al.
ONCOGENE (2018)
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
K. Moore et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Treatment with olaparib monotherapy in the maintenance setting significantly improves progression-free survival in patients with platinum-sensitive relapsed ovarian cancer: Results from the phase III SOLO2 study
E. Pujade-Lauraine et al.
GYNECOLOGIC ONCOLOGY (2017)
Targeting of Wnt/β-Catenin by Anthelmintic Drug Pyrvinium Enhances Sensitivity of Ovarian Cancer Cells to Chemotherapy
Chongyuan Zhang et al.
MEDICAL SCIENCE MONITOR (2017)
Epidemiology of epithelial ovarian cancer
Penelope M. Webb et al.
BEST PRACTICE & RESEARCH CLINICAL OBSTETRICS & GYNAECOLOGY (2017)
MicroRNA-126 increases chemosensitivity in drug-resistant gastric cancer cells by targeting EZH2
Ping Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2016)
The rise of genomic profiling in ovarian cancer
Rebecca A. Previs et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2016)
Precision targeted therapy of ovarian cancer
Justin Sapiezynski et al.
JOURNAL OF CONTROLLED RELEASE (2016)
EZH2 inhibition promotes epithelial-to-mesenchymal transition in ovarian cancer cells
Horacio Cardenas et al.
ONCOTARGET (2016)
MiR-138 Acts as a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells
Ziqiang Zhu et al.
PLOS ONE (2016)
The inhibition of EZH2 ameliorates osteoarthritis development through the Wnt/β-catenin pathway
Linwei Chen et al.
SCIENTIFIC REPORTS (2016)
Elevated β-catenin activity contributes to carboplatin resistance in A2780cp ovarian cancer cells
Samir H. Barghout et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
PARP inhibitors in ovarian cancer: Clinical evidence for informed treatment decisions
Jonathan A. Ledermann et al.
BRITISH JOURNAL OF CANCER (2015)
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers
Guoyan Liu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
Augmentation of Response to Chemotherapy by microRNA-506 Through Regulation of RAD51 in Serous Ovarian Cancers
Guoyan Liu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer
Yan Sun et al.
JOURNAL OF PATHOLOGY (2015)
An update on PARP inhibitors-moving to the adjuvant setting
Amir Sonnenblick et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/β-catenin/Snail signaling pathway
Hao Wang et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2014)
MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer
Guoyan Liu et al.
JOURNAL OF PATHOLOGY (2014)
Integrated Analyses Identify a Master MicroRNA Regulatory Network for the Mesenchymal Subtype in Serous Ovarian Cancer
Da Yang et al.
CANCER CELL (2013)
The Wnt/β-catenin pathway in ovarian cancer: A review
Rebecca C. Arend et al.
GYNECOLOGIC ONCOLOGY (2013)
Sorafenib sensitizes hepatocellular carcinoma cell to cisplatin via suppression of Wnt/β-catenin signaling
Yongpeng Wei et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2013)
PAF and EZH2 Induce Wnt/β-Catenin Signaling Hyperactivation
Hae-Yun Jung et al.
MOLECULAR CELL (2013)
Emerging treatment options for recurrent ovarian cancer: the potential role of olaparib
Heather M. Shaw et al.
ONCOTARGETS AND THERAPY (2013)
FoxM1 and Wnt/β-Catenin Signaling in Glioma Stem Cells
Aihua Gong et al.
CANCER RESEARCH (2012)
Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome
Zhigang C. Wang et al.
CLINICAL CANCER RESEARCH (2012)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Inhibition of Tankyrases Induces Axin Stabilization and Blocks Wnt Signalling in Breast Cancer Cells
Renyue Bao et al.
PLOS ONE (2012)
FoxM1 Promotes β-Catenin Nuclear Localization and Controls Wnt Target-Gene Expression and Glioma Tumorigenesis
Nu Zhang et al.
CANCER CELL (2011)
EZH2 Promotes Expansion of Breast Tumor Initiating Cells through Activation of RAF1-β-Catenin Signaling
Chun-Ju Chang et al.
CANCER CELL (2011)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines
Smriti Kumar et al.
JOURNAL OF OVARIAN RESEARCH (2011)
MicroRNA: Biogenesis, Function and Role in Cancer
Leigh-Ann MacFarlane et al.
CURRENT GENOMICS (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Targeting the DNA Damage Response in Cancer
Mats Ljungman
CHEMICAL REVIEWS (2009)
4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1
Keith A. Menear et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
MicroRNA signatures in human cancers
George A. Calin et al.
NATURE REVIEWS CANCER (2006)
Share Paper
